제품 수집
제품 세부정보
Synonyms
ACE-2, ACEH, ACE2
Source
PE-Labeled Human ACE2, His Tag (AC2-HP2H3) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).
Predicted N-terminus: Gln 18
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-ELISA
Immobilized SARS S protein RBD, His Tag (Cat. No. SPD-S52H6) at 5 μg/mL (100 μL/well) can bind PE-Labeled Human ACE2, His Tag (Cat. No. AC2-HP2H3) with a linear range of 0.078-20 μg/mL (QC tested).
Protocol
Bioactivity-FACS
Biotinylated SARS-CoV-2 Spike RBD Protein, His, Avitag™ (MALS verified) (Cat. No. SPD-C82E9) at 10pg/bead on Recombinant Streptavidin Protein (Cat. No. STN-N5116) at 2.5pg/bead were conjugated to fluorochrome-encoded microspheres. Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (MALS verified) (Cat. No. SPD-M265) competes with PE-Labeled Human ACE2, His tag (Cat. No. AC2-HP2H3) for binding to Biotinylated SARS-CoV-2 Spike RBD Protein encapsulated beads with a linear range of 16.25-8320 ng/mL.
사용자 리뷰 댓글 남기기
배경 소개
프론티어 진행
의약품 개발 진행- 영어 이름：
Angiotensin-converting enzyme 2
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
7 상세
- 최고 개발 단계：
Phase 2 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
